

David Cooper

Discloser Identifier: 970668

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Vaccine Researcher
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
Additional Information:		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Luke Cunliffe

Discloser Identifier: 1049038

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Limited	Employment	Self
<i>Title:</i> Clinical Scientist  <i>Additional Information:</i>		<i>Position Description:</i> Responsible for bringing together clinical, scientific and technical disciplines to ensure high quality protocol development, study execution and data interpretation.

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 633943

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> Hanna Czajka <i>Grant / Contract Description:</i> Conducting as principal investigator clinical trials and giving lectures contracted by AstraZeneca <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i>		
GlaxoSmithKline	Grant / Contract	Self
<i>Recipient Name:</i> Hanna Czajka <i>Grant / Contract Description:</i> Conducting as principal investigator clinical trials and giving lectures contracted by GSK. <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i>		
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Hanna Czajka <i>Grant / Contract Description:</i> Conducting as principal investigator clinical trials and giving lectures contracted by Pfizer <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i>		
SANOPI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> Hanna Czajka <i>Grant / Contract Description:</i> Conducting as principal investigator clinical trials and giving lectures contracted by Sanofi <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i>		

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Joseph Domachowski

Discloser Identifier: 420260

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer International LLC	Other	Self
<i>Category:</i> Other <i>Description:</i> Site investigator for clinical trial <i>Additional Information:</i> Payments made to my employer, SUNY Upstate Medical University on my behalf for clinical trial activities		
SANOPI PASTEUR BIOLOGICS LLC	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory Board for Vaccines and Vaccine confidence <i>Additional Information:</i> I'm paid annual consulting fees for advisory board activities		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 333138

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
AbbVie Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Antiviral therapies <i>Additional Information:</i>		
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
meissa vaccines	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant for respiratory vaccines <i>Additional Information:</i>		
Moderna	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant for respiratory virus vaccines <i>Additional Information:</i>		
Pfizer Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> RSV treatment <i>Additional Information:</i>		
SANOPI PASTEUR INC.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> RSV prevention <i>Additional Information:</i>		

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

**3. Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 627453

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Vice President <i>Additional Information:</i>		<i>Position Description:</i> Vaccine Clinical Research and Development Worldwide Research Development and Medical
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children Less than 5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Alejandra Gurtman

Discloser Identifier: 633953

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> VP Vaccine Clinical Research and Development <i>Additional Information:</i>		<i>Position Description:</i>

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Flor M. Muñoz, MD,1 Lawrence D. Sher, MD,2 Charu Sabharwal, MD, MPH,3 Alejandra Gurtman, MD,3 Xia Xu, PhD,4 Nicholas Kitchin, MD,5 Stephen Lockhart, DM,5 Robert Riesenber, MD,6 Joanna M. Sexter, MD,7 Hanna Czajka, MD,8 Grant C. Paulsen, MD,9 Yvonne Maldonado, MD,10 Emmanuel B. Walter, MD,11 Kawsar R. Talaat, MD,12 Janet A. Englund, MD,13 Uzma N. Sarwar, MD,3 Caitlin Hansen, MD, MPH,3 Martha Iwamoto, MD,3 Chris Webber, MD,5 Luke Cunliffe, BSc,5 Benita Ukkonen, MD,14 Silvina Natalini Martínez, MD,15 Barbara A. Pahud, MD, MPH,3 Iona Munjal, MD,3 Joseph B. Domachowske, MD,16 Kena A. Swanson, PhD,3 Hua Ma, PhD,4 Kenneth Koury, PhD,3 Susan Mather, MD,17 Claire Lu, PhD,3 Jing Zou, PhD,18 Xuping Xie, PhD,18 Pei-Yong Shi, PhD,18 David Cooper, PhD,3 Özlem Türeci, MD,19 Uğur Şahin, MD,19 Kathrin U. Jansen, PhD,3 and William C. Gruber, MD,3 on behalf of the C4591007 Clinical Trial Group

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Caitlin Hansen

**Discloser Identifier:** 1092655

**Disclosure Purpose:** 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Associate Director <i>Additional Information:</i>		<i>Position Description:</i> Medical Monitor, Vaccine Clinical Research and Development

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Martha Iwamoto

Discloser Identifier: 1092656

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Clinician medical monitor <i>Additional Information:</i>		<i>Position Description:</i> Provide medical and scientific expertise and oversight for specific clinical trials
Pfizer Inc.	Stock Option	Self
Additional Information:		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

"Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old"

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 627443

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> vaccine consultant <i>Additional Information:</i> less than 10 hours a week		
Pfizer Inc.	Stock	Self
<i>Additional Information:</i> shareholder		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children Less than 5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Nicholas Kitchin

Discloser Identifier: 970660

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President <i>Additional Information:</i> Full time employee		<i>Position Description:</i> Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
Additional Information:		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Kenneth Koury

Discloser Identifier: 970666

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Head of Statistics and Modeling, Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 970661

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President <i>Additional Information:</i>		<i>Position Description:</i> Clinical Research Head Vaccines Europe and Asia Pacific
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
Additional Information:		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Claire Lu

Discloser Identifier: 1063600

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Hua Ma

Discloser Identifier: 1017533

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director, Biostatistics <i>Additional Information:</i>		<i>Position Description:</i> Clinical trial statistician
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Yvonne Maldonado

Discloser Identifier: 494910

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Stanford University School of Medicine <i>Grant / Contract Description:</i> Pfizer Pediatric COVID-19 Vaccine Clinical Trials <i>Additional Information:</i> Stanford Site Principal Investigator for Pfizer Pediatric Vaccine Clinical Trials <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Stanford University School of Medicine <i>Grant / Contract Description:</i> Pfizer Maternal RSV Vaccine Clinical Trial <i>Additional Information:</i> Stanford Site Principal Investigator for this vaccine trial <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Pfizer Inc.	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> Member, DSMB, Pfizer Meningococcal Vaccines Clinical Trials <i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Susan Mather

Discloser Identifier: 992091

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i>		<i>Position Description:</i> Safety physician
Pfizer	Stock	Self
<i>Additional Information:</i> Stock and stock options based on employment policies		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 995102

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i> full time		<i>Position Description:</i> Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Flor Munoz

Discloser Identifier: 456309

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> Member Data Safety Monitoring Committee various vaccines including COVID <i>Additional Information:</i>		
Pfizer Inc.	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> Member Data Safety Monitoring Committee - RSV vaccines <i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children < 5 years old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Discloser Identifier:** 1092657

**Disclosure Purpose:** 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Laboratorios Pfizer Ltda.	Other	Self
<p><i>Category:</i> Other  <i>Description:</i> I am principal investigator of the clinical trial.  <i>Additional Information:</i></p>		

## Additional Questions

**1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

**a. Please describe those relationships.**

Investigator of the clinical trial that is exposed in the article.

**2. What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

**3. Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1049035

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Merck	Consultant	Self
<p><i>Category:</i> Consultant  <i>Description:</i> service on US Vaccine Confidence Expert Input Forum  <i>Additional Information:</i> Presented and participated at forum</p>		
Pfizer	Consultant	Self
<p><i>Category:</i> Consultant  <i>Description:</i> Consultant for Trumenba Science Story  <i>Additional Information:</i> limited time consultant for topic specific story</p>		
Pfizer	Consultant	Self
<p><i>Category:</i> Consultant  <i>Description:</i> Consultant for Virtual Discussion about future pediatric PCV recommendations in the US  <i>Additional Information:</i> Consultant for one time meeting on topic specific discussion</p>		
Pfizer	Consultant	Self
<p><i>Category:</i> Consultant  <i>Description:</i> Consultant for Spring 2021 Trumenba Premiere Broadcast  <i>Additional Information:</i> Limited time Consultant for topic specific broadcast</p>		
Pfizer	Consultant	Self
<p><i>Category:</i> Consultant  <i>Description:</i> Consultant for Pediatric Pneumococcal PEGASUS  <i>Additional Information:</i> Time limited consultant for topic specific activity</p>		
SANOPI PASTEUR INC.	Consultant	Self
<p><i>Category:</i> Consultant  <i>Description:</i> Scientific consultant &amp; Medical Expert  <i>Additional Information:</i> limited time scientific/vaccine consultant for the production of educational videos to support HCPs in managing vaccine hesitancy</p>		
SANOPI PASTEUR INC.	Consultant	Self
<p><i>Category:</i> Consultant  <i>Description:</i> Presented at the International Forum Voices for Vaccination on 8/29/19 in Mexico City, MX  <i>Additional Information:</i> Hotel and flight was booked by the funder</p>		
SANOPI PASTEUR INC.	Consultant	Self



Entity	Type	Interest Held By
<p><i>Category:</i> Consultant <i>Description:</i> provided presentations as requested <i>Additional Information:</i> Served as speaker to healthcare professionals on topics specific to vaccines &amp; vaccine hesitancy</p>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

- a. **Please describe those relationships.**

I currently am an employee of Pfizer

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Grant Paulsen

**Discloser Identifier:** 1049029

**Disclosure Purpose:** 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna, inc	Grant / Contract	Self
<i>Recipient Name:</i> Cincinnati Children's Hospital Medical Center. Paulsen - Site PI <i>Grant / Contract Description:</i> Received institutional grant support for role as the Site PI for Moderna KidCOVE vaccine trial. <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
PFIZER CANADA INC	Grant / Contract	Self
<i>Recipient Name:</i> Grant Paulsen <i>Grant / Contract Description:</i> Grant/Contract support from Pfizer to conduct a clinical vaccine trial. <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Robert Riesenber

**Discloser Identifier:** 738752

**Disclosure Purpose:** 22-11031

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Discloser Identifier:** 995101

**Disclosure Purpose:** 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i> Medical Monitor within Vaccine Clinical Research and Development

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 970674

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Executive Officer, Co-Founder <i>Additional Information:</i>		<i>Position Description:</i> Member of the Board
biontech	Stock	Self
<i>Additional Information:</i>		
biontech	Stock Option	Self
Additional Information:		

### Intellectual Property

Type	Is Licensed	Interest Held By
Patent - 3 UTR Sequences for stabilisation of mRNA	-	Self
<i>Description:</i> 3 UTR Sequences for stabilisation of mRNA <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> USA <i>Licensees:</i>		<i>Patent Number:</i> EPPCT/EP2015/073180, US 20190071682 <i>Patent Holder:</i> Previous Institution
Licensee	Title	Date
biontech		
<i>Additional Information:</i> I am co-inventors on various patents on RNA Technologies, both pending and granted, which have been filed over a period of 10+ years, some of which are licensed to third parties. Jurisdictions are Broad including US, EU, Asia.		

### Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



**Discloser Identifier:** 1049037

**Disclosure Purpose:** 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Associate Director <i>Additional Information:</i>		<i>Position Description:</i> Medical Monitor

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Discloser Identifier:** 1092650

**Disclosure Purpose:** 22-11031

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

22-11031 Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



lawrence sher

Discloser Identifier: 570023

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Clinical Trial <i>Additional Information:</i>		
Pfizer Inc.	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trial <i>Additional Information:</i>		
Regeneron Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> Peninsula Research Associates <i>Grant / Contract Description:</i> Clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
SANOPI PASTEUR BIOLOGICS LLC	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory counsel <i>Additional Information:</i>		
SANOPI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> Peninsula Research Associates <i>Grant / Contract Description:</i> Clinical Trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes.

a. Please describe those relationships.

Clinal research trial

2. What is the manuscript title?

"Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Pei-Yong Shi

**Discloser Identifier:** 717400

**Disclosure Purpose:** 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Pei-Yong Shi <i>Grant / Contract Description:</i> Contract <i>Additional Information:</i> Sample testing		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Kena Swanson

Discloser Identifier: 970664

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President, Viral Vaccines <i>Additional Information:</i>		<i>Position Description:</i> vaccine research and development
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 688109

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Johns Hopkins University <i>Grant / Contract Description:</i> To conduct 3 clinical trials of the Pfizer-BioNTech vaccine in adults and children. I am the PI. <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
SANOFI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> Johns Hopkins University <i>Grant / Contract Description:</i> To conduct a yellow fever vaccine trial; I am the PI of the trial. <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Discloser Identifier:** 970670

**Disclosure Purpose:** 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
biontech	Employment	Self
<p><i>Title:</i> Chief Medical Officer <span style="float: right;"><i>Position Description:</i> Board member, CO-founder</span>  <i>Additional Information:</i> also spouse is board member and CEO of Company since 2008</p>		
biontech	Fiduciary Officer	Self
<p><i>Official Title:</i> Chief Medical Officer <span style="float: right;"><i>Position Description:</i> board member, co-founder</span>  <i>Additional Information:</i> also spouse is co-founder and board member (Chief Executive Officer) of Biontech</p>		
biontech	Stock	Spouse/Partner
<p><i>Additional Information:</i> founder, shareholder</p>		
biontech	Stock Option	Self
<p><i>Additional Information:</i> self and spouse have stock Options. spouse has stock</p>		

### Intellectual Property

Type	Is Licensed	Interest Held By						
Patent - Modifications of RNA leading to increased transcr	-	Self						
<p><i>Description:</i> Modifications of RNA leading to increased transcript stability and translational efficiency <span style="float: right;"><i>Patent Number:</i> EP1934345B9, DE102005046490.4</span>  <i>Patent Status:</i> Pending <span style="float: right;"><i>Patent Holder:</i> Current Institution</span>  <i>Filing Jurisdiction:</i> USA  <i>Licensees:</i></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>biontech</td> <td></td> <td></td> </tr> </tbody> </table> <p><i>Additional Information:</i> self and spouse are co-inventors on various patents on RNA Tech</p>			Licensee	Title	Date	biontech		
Licensee	Title	Date						
biontech								

### Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

**2. What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old,

**3. Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Benita Ukkonen

**Discloser Identifier:** 1088770

**Disclosure Purpose:** 22-11031

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 592797

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
CSL Sequiris	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Conduct of Feasibility Assessment <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
ILiAD Biotechnologies	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consult on product development <i>Additional Information:</i>		
Moderna	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Conduct of Clinical Trial <i>Additional Information:</i> Co-investigator for Clinical trial		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Conduct of Pfizer/BioNTech COVID-19 vaccine studies <i>Additional Information:</i> Principal investigator for clinical trials		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Vaxcyte	Other	Self
<i>Category:</i> Other <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i> No financial compensation as of this time		

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 627370

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer, Ltd	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Vaccines Clinical Research and Development
Pfizer, Ltd	Stock	Self
<i>Additional Information:</i>		
Pfizer, Ltd	Stock Option	Self
Additional Information:		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 996937

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Xuping Xie <i>Grant / Contract Description:</i> Pfizer's contract supports the testing of the specimens <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children &lt;5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1017534

Disclosure Purpose: 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Sr. Director, Vaccine Statistics <i>Additional Information:</i>		<i>Position Description:</i> Design, conduct, and analysis of vaccine clinical trials

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Discloser Identifier:** 996939

**Disclosure Purpose:** 22-11031

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Jing Zou <i>Grant / Contract Description:</i> Pfizer's contract supports the testing of the specimens <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Evaluation of BNT162b2 COVID-19 mRNA Vaccine in Children <5 Years Old

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.